Healthcare -
Biotechnology - NASDAQ - US
$ 6.3
-0.865 %
$ 1 B
Market Cap
-5.16
P/E
1. INTRINSIC VALUE
Balance Sheet
Ocular Therapeutix, Inc.
| Current Assets | 441 M |
| Cash & Short-Term Investments | 392 M |
| Receivables | 32.4 M |
| Other Current Assets | 16.5 M |
| Non-Current Assets | 16.9 M |
| Long-Term Investments | 0 |
| PP&E | 15.3 M |
| Other Non-Current Assets | 1.61 M |
| Current Liabilities | 41.4 M |
| Accounts Payable | 4.18 M |
| Short-Term Debt | 1.93 M |
| Other Current Liabilities | 35.2 M |
| Non-Current Liabilities | 101 M |
| Long-Term Debt | 73.8 M |
| Other Non-Current Liabilities | 27.4 M |
EFFICIENCY
Earnings Waterfall
Ocular Therapeutix, Inc.
| Revenue | 63.7 M |
| Cost Of Revenue | 5.63 M |
| Gross Profit | 58.1 M |
| Operating Expenses | 230 M |
| Operating Income | -172 M |
| Other Expenses | 21.7 M |
| Net Income | -194 M |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Ocular Therapeutix, Inc.
| Net Income | -194 M |
| Depreciation & Amortization | 3.79 M |
| Capital Expenditures | -1.29 M |
| Stock-Based Compensation | 33.1 M |
| Change in Working Capital | 0 |
| Others | 21.9 M |
| Free Cash Flow | -136 M |
Wall Street Analysts Price Targets
Ocular Therapeutix, Inc.
Wall Street analysts predict an average 1-year price target for OCUL of $16.2 , with forecasts ranging from
a
low of
$14 to a high of $19 .
OCUL Lowest Price Target
Wall Street Target
14 USD
122.22%
OCUL Average Price Target
Wall Street Target
16.2 USD
157.94%
OCUL Highest Price Target
Wall Street Target
19 USD
201.59%
4. DIVIDEND
ANALYSIS
OCUL does not distribute dividends.
5. COMPETITION
6. Ownership
Insider Ownership
Ocular Therapeutix, Inc.
Sold
0-3 MONTHS
338 K USD 5
3-6 MONTHS
255 K USD 4
6-9 MONTHS
205 K USD 2
9-12 MONTHS
138 K USD 2
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Ocular Therapeutix™ to Participate in Two Investor Conferences in April
BEDFORD, Mass., March 31, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), a biopharmaceutical company committed to redefining the retina experience, today announced that the Company will participate in two investor conferences in April:
globenewswire.com
- 3 weeks ago
Why Ocular Therapeutix Was Bumping Higher This Week
The market was seeing Ocular Therapeutix (OCUL -6.52%) very positively this week, and that sunny view pushed the company's stock higher.
fool.com
- 1 month ago
Ocular Therapeutix Axpaxli Advances In Phase 3 For Wet AMD, Analyst Forecasts Huge Upside
Needham initiated coverage on Ocular Therapeutix Inc OCUL, noting the company's lead asset, Axpaxli, an investigational axitinib-based intravitreal implant for wet age-related macular degeneration (wet AMD).
benzinga.com
- 1 month ago
Ocular Therapeutix: Axpaxli's Dual Trial Strategy And Blockbuster Potential
Ocular Therapeutix focuses on Axpaxli, a long-acting wet AMD therapy administered every 6-12 months. Dextenza currently drives revenues, but Axpaxli is expected to unlock long-term growth. Ocular has two important Phase 3 trials (SOL-1 and SOL-R), which are key catalysts this year, with data expected by early 2026.
seekingalpha.com
- 1 month ago
Ocular Therapeutix (OCUL) Reports Q4 Loss, Tops Revenue Estimates
Ocular Therapeutix (OCUL) came out with a quarterly loss of $0.29 per share versus the Zacks Consensus Estimate of a loss of $0.24. This compares to loss of $0.28 per share a year ago.
zacks.com
- 1 month ago
Ocular Therapeutix™ to Report Fourth Quarter and Full Year 2024 Results on March 3, 2025
BEDFORD, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), a biopharmaceutical company committed to redefining the retina experience, today announced that it plans to host a conference call and webcast on Monday, March 3, 2025, at 8:00 AM ET to discuss recent business progress and financial results for the fourth quarter and full year ended December 31, 2024.
globenewswire.com
- 1 month ago
Ocular Therapeutix™ Announces Upcoming Presentations at the Angiogenesis, Exudation, and Degeneration 2025 Virtual Meeting
BEDFORD, Mass., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), a biopharmaceutical company committed to redefining the retina experience, today announced upcoming presentations at the Angiogenesis, Exudation, and Degeneration 2025 virtual meeting on February 8, 2025.
globenewswire.com
- 2 months ago
Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
BEDFORD, Mass., Jan. 17, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”, the “Company”), a biopharmaceutical company committed to redefining the retina experience, today announced that it has granted inducement awards to one newly hired employee. The awards were made as inducements material to the individual's acceptance of employment with Ocular under Ocular's 2019 Inducement Stock Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4).
globenewswire.com
- 3 months ago
Ocular Therapeutix™ Shares SOL-R Enrollment Progress and Next Steps for AXPAXLI™ in NPDR
311 subjects enrolled across various stages of loading and randomization in SOL-R, Ocular's second registrational trial of AXPAXLI™ in wet AMD, as of January 10, 2024
globenewswire.com
- 3 months ago
Ocular Is Now Thoroughly Derisked
Ocular Therapeutics' OTX-TKI implant offers a cost-effective, long-lasting alternative to gene therapies for wet AMD, showing superior duration and comparable efficacy to Regeneron's Eylea. Recent FDA approval for trial modifications and positive phase 1 results in NPDR patients enhance OTX-TKI's potential, with phase 3 data expected by Q4 2025. Financially, OCUL is strong with a $1.34bn market cap and $427mn cash, ensuring a runway of 8-9 quarters despite high R&D expenses.
seekingalpha.com
- 3 months ago
Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
BEDFORD, Mass., Dec. 13, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, “Ocular”), a biopharmaceutical company committed to improving vision in the real world through the development and commercialization of innovative therapies for retinal diseases and other eye conditions, today announced that it has agreed to grant inducement awards to one newly hired employee. The awards were made as inducements material to the individual's acceptance of employment with Ocular under Ocular's 2019 Inducement Stock Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4).
globenewswire.com
- 4 months ago
Ocular Therapeutix™ to Present at the 43rd Annual J.P. Morgan Healthcare Conference
BEDFORD, Mass., Dec. 10, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”, the “Company”), a biopharmaceutical company committed to improving vision in the real world through the development and commercialization of innovative therapies for retinal diseases and other eye conditions, today announced that the Company will present at the 43rd Annual J.P. Morgan Healthcare Conference to be held January 13-16, 2025 in San Francisco, CA.
globenewswire.com
- 4 months ago
8. Profile
Summary
Ocular Therapeutix, Inc. OCUL
COUNTRY
US
INDUSTRY
Biotechnology
MARKET CAP
$ 1 B
Dividend Yield
0.00%
Description
Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology. The company markets ReSure Sealant, an ophthalmic device to prevent wound leaks in corneal incisions following cataract surgery; and DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing OTX-TKI, an axitinib intravitreal implant that is in phase 1 clinical trials for the treatment of wet age-related macular degeneration and other retinal diseases; OTX-TIC, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the Company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC, as well as a discovery collaboration with Mosaic Biosciences to identify new targets and therapeutic agents for the treatment of dry age-related macular degeneration (dMAD). Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.
Contact
24 Crosby Drive, Bedford, MA, 01730
https://www.ocutx.com
IPO
Date
July 25, 2014
Employees
274
Officers
Dr. Pravin U. Dugel M.D.
Executive Chairman, President & Chief Executive Officer
Mr. Steve Meyers
Chief Commercial Officer
Mr. Barry Rubenstein M.S.
Chief Human Resources Officer
Mr. William S. Slattery Jr.
Vice President of Investor Relations
Dr. Peter K. Kaiser M.D.
Chief Development Officer
Dr. Jeffrey S. Heier M.D.
Chief Scientific Officer
Mr. Todd D.C. Anderman J.D.
Chief Legal Officer & Corporate Secretary
Mr. Donald Notman Jr.
Chief Financial Officer, Chief Operating Officer & Principal Accounting Officer
Dr. Peter K. Jarrett Ph.D.
Chief Technology Officer
Mr. William H. Ransone II
Vice President of Global Sales & Marketing